VALENCIA, Calif., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Envoy Group Corp. (OTC:ENVV) is pleased to announce it has signed a consulting agreement with McCarthy Consultant Services Inc. of Newmarket, Ontario.
In operation for over 35 years, McCarthy Consultant Services Inc. (MCSI) has evolved into an industry leader across Canada and throughout the world. MCSI is trusted and valued by the pharmaceutical, biotechnology, medical device, cosmetic, natural health products and food industries for its efficient, timely, and effective regulatory work. The MCSI regulatory team, one of the largest in Canada, have extensive background working in these highly regulated and constantly evolving industries. MCSI also has the capability to handle regulatory needs in the U.S. and the E.U.
Under the terms of the agreement, MCSI will act as the key service provider allowing Envoy to successfully navigate our Louis XIV Energy product line through the Canadian regulatory landscape for importing, packaging, labeling, distribution and manufacturing practices.
Envoy has previously announced it was moving into the $50 Billion dollar Energy drink market with the exclusive distribution rights for the full family of Louis XIV Energy Drinks. Previously only available in Europe, the Louis XIV Energy Drinks are crafted to produce an ideal balance of high energy and incredible taste.
Harp Sangha added “we are pleased to be working with McCarthy Consultants, their expertise in all regulatory matters will allow Envoy to greatly expedite our product roll out to the very active energy drink market.”
Envoy’s comprehensive marketing and distribution campaign is currently in the works and product roll out will commence as soon as regulatory measures are met.
Envoy Group website link http://envoygroupcorp.com/lxiv/
Louis XIV website link: http://www.louisxivenergy.com/en/
Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “estimates”, “intends” or “believes”, or that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur”, or “be achieved”. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
Source:ENVOY GROUP CORP